Avidity Biosciences, Inc. (RNA), a San Diego–based biotechnology company pioneering antibody oligonucleotide conjugates (AOCs), is preparing for a $600 million initial public offering (IPO) expected in the first half of 2026. The company aims to accelerate late-stage clinical trials for its breakthrough RNA therapies targeting rare muscle and cardiac disorders. This IPO marks a pivotal moment for RNA-based medicine, offering investors a rare opportunity to back a company at the forefront of next-generation genetic treatments.
Company Background
Founded in 2012 and headquartered in San Diego, California, Avidity Biosciences specializes in the development of RNA therapeutics designed to address diseases previously considered untreatable. Its proprietary AOC platform uniquely combines the targeting capabilities of monoclonal antibodies with the precision of RNA-based therapeutics, enabling delivery directly to affected tissues. The company’s robust pipeline includes three leading programs in advanced clinical stages:
-
Delpacibart etedesiran (Phase 3): for myotonic dystrophy type 1,
-
Delpacibart braxlosiran (Phase 1/2): for facioscapulohumeral muscular dystrophy, and
-
Delpacibart zotadirsen (Phase 2): for Duchenne muscular dystrophy.
In addition to these flagship programs, Avidity is expanding into precision cardiology, developing candidates such as AOC 1086 and AOC 1072 for rare genetic cardiomyopathies. Led by a world-class management team and backed by institutional investors specializing in biotechnology innovation, Avidity has established itself as one of the most promising biotech firms in the RNA therapy space.
